T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
T2 Biosystems received FDA clearance to market its T2Candida Panel for pediatric patients, enabling faster detection of sepsis-causing Candida species directly from blood in 3-5 hours.
Reference News
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
T2 Biosystems received FDA clearance to market its T2Candida Panel for pediatric patients, enabling faster detection of sepsis-causing Candida species directly from blood in 3-5 hours.